Bristol-Myers Squibb Company PFD CONV 2
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection. Its products include Opdivo, a biological product for anti-cancer indications; Eliquis… Read more
Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) - Total Assets
Latest total assets as of September 2024: $93.67 Billion USD
Based on the latest financial reports, Bristol-Myers Squibb Company PFD CONV 2 (BMYMP) holds total assets worth $93.67 Billion USD as of September 2024.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Bristol-Myers Squibb Company PFD CONV 2 - Total Assets Trend (1987–2023)
This chart illustrates how Bristol-Myers Squibb Company PFD CONV 2’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Bristol-Myers Squibb Company PFD CONV 2 - Asset Composition Analysis
Current Asset Composition (December 2023)
Bristol-Myers Squibb Company PFD CONV 2's total assets of $93.67 Billion consist of 33.4% current assets and 66.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.1% |
| Accounts Receivable | $15.26 Billion | 16.0% |
| Inventory | $2.66 Billion | 2.8% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $27.07 Billion | 28.5% |
| Goodwill | $21.17 Billion | 22.3% |
Asset Composition Trend (1987–2023)
This chart illustrates how Bristol-Myers Squibb Company PFD CONV 2's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Bristol-Myers Squibb Company PFD CONV 2's current assets represent 33.4% of total assets in 2023, a decrease from 66.6% in 1987.
- Cash Position: Cash and equivalents constituted 12.1% of total assets in 2023, down from 31.2% in 1987.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 50.0% of total assets, an increase from 2.0% in 1987.
- Asset Diversification: The largest asset category is intangible assets at 28.5% of total assets.
Bristol-Myers Squibb Company PFD CONV 2 Competitors by Total Assets
Key competitors of Bristol-Myers Squibb Company PFD CONV 2 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MANHATTAN ASSOC
BE:MHT
|
Germany | €698.14 Million |
|
TV BROADCAST
MU:TBCN
|
Germany | €6.25 Billion |
|
FIRST CITIZENS BC A
BE:FC6A
|
Germany | €220.57 Billion |
|
COSTCO WHSL
MU:CTO
|
Germany | €69.83 Billion |
|
GOLDMAN SACHS GROUP - Dusseldorf Stock Exchang
DU:GOS
|
Germany | €1.73 Trillion |
|
BURCKHARDT COMPRE N
MU:B5H
|
Germany | €1.07 Billion |
|
Public Service Company of New Mexico PFD 4.58%
PINK:PNMXO
|
USA | $886.19 Million |
|
General Mills Inc
NYSE:GIS
|
USA | $32.55 Billion |
Bristol-Myers Squibb Company PFD CONV 2 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Bristol-Myers Squibb Company PFD CONV 2 generates 0.47x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Solid ROA - For every $100 in assets, Bristol-Myers Squibb Company PFD CONV 2 generates $8.43 in net profit.
Bristol-Myers Squibb Company PFD CONV 2 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.24 | 1.18 | 1.60 |
| Quick Ratio | 1.09 | 1.07 | 1.37 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.44 Billion | $ 4.17 Billion | $ 11.05 Billion |
Bristol-Myers Squibb Company PFD CONV 2 - Advanced Valuation Insights
This section examines the relationship between Bristol-Myers Squibb Company PFD CONV 2's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | - |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -1.7% |
| Total Assets | $95.16 Billion |
| Market Capitalization | $9.45 Million USD |
Valuation Analysis
Below Book Valuation: The market values Bristol-Myers Squibb Company PFD CONV 2's assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Bristol-Myers Squibb Company PFD CONV 2's assets decreased by 1.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Bristol-Myers Squibb Company PFD CONV 2 (1987–2023)
The table below shows the annual total assets of Bristol-Myers Squibb Company PFD CONV 2 from 1987 to 2023.
| Year | Total Assets | Change |
|---|---|---|
| 2023-12-31 | $95.16 Billion | -1.72% |
| 2022-12-31 | $96.82 Billion | -11.43% |
| 2021-12-31 | $109.31 Billion | -7.74% |
| 2020-12-31 | $118.48 Billion | -8.82% |
| 2019-12-31 | $129.94 Billion | +1119.10% |
| 2018-12-31 | $10.66 Billion | -68.23% |
| 2017-12-31 | $33.55 Billion | -0.46% |
| 2016-12-31 | $33.71 Billion | +6.17% |
| 2015-12-31 | $31.75 Billion | -5.93% |
| 2014-12-31 | $33.75 Billion | -12.55% |
| 2013-12-31 | $38.59 Billion | +7.51% |
| 2012-12-31 | $35.90 Billion | +8.88% |
| 2011-12-31 | $32.97 Billion | +6.09% |
| 2010-12-31 | $31.08 Billion | +0.22% |
| 2009-12-31 | $31.01 Billion | +4.93% |
| 2008-12-31 | $29.55 Billion | +12.91% |
| 2007-12-31 | $26.17 Billion | +2.33% |
| 2006-12-31 | $25.57 Billion | -9.11% |
| 2005-12-31 | $28.14 Billion | -7.55% |
| 2004-12-31 | $30.43 Billion | +10.79% |
| 2003-12-31 | $27.47 Billion | +10.44% |
| 2002-12-31 | $24.87 Billion | -8.07% |
| 2001-12-31 | $27.06 Billion | +53.93% |
| 2000-12-31 | $17.58 Billion | +2.71% |
| 1999-12-31 | $17.11 Billion | +5.17% |
| 1998-12-31 | $16.27 Billion | +8.65% |
| 1997-12-31 | $14.98 Billion | +1.99% |
| 1996-12-31 | $14.69 Billion | +5.43% |
| 1995-12-31 | $13.93 Billion | +7.89% |
| 1994-12-31 | $12.91 Billion | +6.69% |
| 1993-12-31 | $12.10 Billion | +12.00% |
| 1992-12-31 | $10.80 Billion | +14.74% |
| 1991-12-31 | $9.42 Billion | +2.18% |
| 1990-12-31 | $9.21 Billion | +8.45% |
| 1989-12-31 | $8.50 Billion | +2.71% |
| 1988-12-31 | $8.27 Billion | +10.10% |
| 1987-12-31 | $7.51 Billion | -- |